{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:43:15Z","timestamp":1783539795647,"version":"3.55.0"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Anti-tumor necrosis factor-\u03b1 (TNF-\u03b1) is a life-changing treatment leading\nto quality-of-life improvement. Nonetheless, this treatment is associated with a high risk of infection,\nespecially tuberculosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Our study aimed to determine the frequency of active tuberculosis in our patients with\nchronic rheumatic disease and treated with TNF-\u03b1.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We conducted a retrospective study including patients with Rheumatoid Arthritis and\nSpondylarthritis diagnosed according to ACR\/EULAR 2009 criteria and ASAS 2010, respectively,\nand treated with biological agents for at least 6 months. We collected data regarding tuberculosis\nscreening and the occurrence of active tuberculosis during follow-up.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>82 patients were included (37 men and 45 women). The mean age was 42 \u00b1 3.4 years. At\ninclusion, no patient had a medical history of tuberculosis. The diagnosis of latent tuberculosis infection\nwas established in 17 patients (20.7%). Prophylactic treatment was prescribed in all these\ncases for three months. Two cases (2.4%) of active tuberculosis occurred under biologic (infliximab).\nIt was two severe forms of tuberculosis. The first case had miliary tuberculosis associated\nwith hepatic and peritoneal involvement. The second one had pleural tuberculosis. These two patients\nreceived anti-tuberculosis therapy, and the biological treatment was interrupted. Given the\nhigh disease activity, the anti-TNF-\u03b1 was restarted after 3 and 4 months. There was no recurrence\nof tuberculosis after 7 years of follow-up.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The use of TNF-\u03b1 blockers is associated with a risk of disseminated forms of tuberculosis.\nTuberculosis screening, which is recommended before the biological onset, is also necessary\nunder this treatment. Restarting the anti-TNF-\u03b1 after appropriate treatment of tuberculosis seemed\nto be safe.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886316666211109092354","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T12:00:27Z","timestamp":1636459227000},"page":"235-240","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tuberculosis Infection Under Anti-TNF Alpha Treatment"],"prefix":"10.2174","volume":"17","author":[{"given":"Maroua","family":"Slouma","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Military Hospital, Faculty of Medicine, El Manar University, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Athimni","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Military Hospital, Faculty of Medicine, El Manar University, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Dhahri","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Military Hospital, Faculty of Medicine, El Manar University, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Gharsallah","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Military Hospital, Faculty of Medicine, El Manar University, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Metoui","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Military Hospital, Faculty of Medicine, El Manar University, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Louzir","sequence":"additional","affiliation":[{"name":"Department\nof Internal Medicine, Faculty of Medicine, Military Hospital, El Manar University, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S28801","volume":"5","author":"Ali T.","year":"2013","unstructured":"Ali T.; Kaitha S.; Mahmood S.; Ftesi A.; Stone J.; Bronze M.S.; Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 2013,5(Mar),79-99","journal-title":"Drug Healthc Patient Saf"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","volume":"47","author":"Xie X.","year":"2014","unstructured":"Xie X.; Li F.; Chen J-W.; Wang J.; Risk of tuberculosis infection in anti-TNF-&#x3B1; biological therapy: From bench to bedside. J Microbiol Immunol Infect 2014,47(4),268-274","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"Gardam M.A.","year":"2003","unstructured":"Gardam M.A.; Keystone E.C.; Menzies R.; Manners S.; Skamene E.; Long R.; Vinh D.C.; Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003,3(3),148-155","journal-title":"Lancet Infect Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"Aletaha D.","year":"2010","unstructured":"Aletaha D.; Neogi T.; Silman A.J.; Funovits J.; Felson D.T.; Bingham C.O.; Birnbaum N.S.; Burmester G.R.; Bykerk V.P.; Cohen M.D.; Combe B.; Costenbader K.H.; Dougados M.; Emery P.; Ferraccioli G.; Hazes J.M.; Hobbs K.; Huizinga T.W.; Kavanaugh A.; Kay J.; Kvien T.K.; Laing T.; Mease P.; M&#xE9;nard H.A.; Moreland L.W.; Naden R.L.; Pincus T.; Smolen J.S.; Stanislawska-Biernat E.; Symmons D.; Tak P.P.; Upchurch K.S.; Vencovsk&#xFD; J.; Wolfe F.; Hawker G.; 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010,62(9),2569-2581","journal-title":"Arthritis Rheum"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"Rudwaleit M.","year":"2009","unstructured":"Rudwaleit M.; Landew&#xE9; R.; van der Heijde D.; Listing J.; Brandt J.; Braun J.; Burgos-Vargas R.; Collantes-Estevez E.; Davis J.; Dijkmans B.; Dougados M.; Emery P.; van der Horst-Bruinsma I.E.; Inman R.; Khan M.A.; Leirisalo-Repo M.; van der Linden S.; Maksymowych W.P.; Mielants H.; Olivieri I.; Sturrock R.; de Vlam K.; Sieper J.; The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009,68(6),770-776","journal-title":"Ann Rheum Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"Rudwaleit M.","year":"2009","unstructured":"Rudwaleit M.; van der Heijde D.; Landew&#xE9; R.; Listing J.; Akkoc N.; Brandt J.; Braun J.; Chou C.T.; Collantes-Estevez E.; Dougados M.; Huang F.; Gu J.; Khan M.A.; Kirazli Y.; Maksymowych W.P.; Mielants H.; S&#xF8;rensen I.J.; Ozgocmen S.; Roussou E.; Valle-O&#xF1;ate R.; Weber U.; Wei J.; Sieper J.; The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis 2009,68(6),777-783","journal-title":"Ann Rheum Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.therap.2017.02.002","volume":"72","author":"Slouma M.","year":"2017","unstructured":"Slouma M.; Mahmoud I.; Saidane O.; Bouden S.; Abdelmoula L.; Latent tuberculosis infection screening prior to biological treatment in Tunisian patients. Therapie 2017,72(5),573-578","journal-title":"Therapie"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"Keane J.","year":"2001","unstructured":"Keane J.; Gershon S.; Wise R.P.; Mirabile-Levens E.; Kasznica J.; Schwieterman W.D.; Siegel J.N.; Braun M.M.; Tuberculosis associated with infliximab, a tumor necrosis factor &#x3B1;-neutralizing agent. N Engl J Med 2001,345(15),1098-1104","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"Solovic I.","year":"2010","unstructured":"Solovic I.; Sester M.; Gomez-Reino J.J.; Rieder H.L.; Ehlers S.; Milburn H.J.; Kampmann B.; Hellmich B.; Groves R.; Schreiber S.; Wallis R.S.; Sotgiu G.; Sch&#xF6;lvinck E.H.; Goletti D.; Zellweger J.P.; Diel R.; Carmona L.; Bartalesi F.; Ravn P.; Bossink A.; Duarte R.; Erkens C.; Clark J.; Migliori G.B.; Lange C.; The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J 2010,36(5),1185-1206","journal-title":"Eur Respir J"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJMcp1005750","volume":"364","author":"Horsburgh C.R.","year":"2011","unstructured":"Horsburgh C.R.; Rubin E.J.; Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011,364(15),1441-1448","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/rheumatology\/kei103","volume":"44","author":"Ledingham J.","year":"2005","unstructured":"Ledingham J.; Wilkinson C.; Deighton C.; British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-&#x3B1; treatments. Rheumatology (Oxford) 2005,44(10),1205-1206","journal-title":"Rheumatology (Oxford)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/424455","volume":"39","author":"Wallis R.S.","year":"2004","unstructured":"Wallis R.S.; Broder M.; Wong J.; Beenhouwer D.; Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004,39(8),1254-1255","journal-title":"Clin Infect Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ncprheum0336","volume":"2","author":"Winthrop K.L.","year":"2006","unstructured":"Winthrop K.L.; Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006,2(11),602-610","journal-title":"Nat Clin Pract Rheumatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"Dixon W.G.","year":"2010","unstructured":"Dixon W.G.; Hyrich K.L.; Watson K.D.; Lunt M.; Galloway J.; Ustianowski A.; Symmons D.P.; Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010,69(3),522-528","journal-title":"Ann Rheum Dis"},{"key":"ref=15","year":"2018","unstructured":"Global Tuberculosis Programme. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Available from:\n2018"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","volume":"372","author":"Getahun H.","year":"2015","unstructured":"Getahun H.; Matteelli A.; Chaisson R.E.; Raviglione M.;  N Engl J Med 2015,372(22),2127-2135","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jinf.2014.10.019","volume":"70","author":"Hur Y-G.","year":"2015","unstructured":"Hur Y-G.; Kang Y.A.; Jang S-H.; Hong J.Y.; Kim A.; Lee S.A.; Kim Y.; Cho S.N.; Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects. J Infect 2015,70(4),346-355","journal-title":"J Infect"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1465-9921-7-56","volume":"7","author":"Brock I.","year":"2006","unstructured":"Brock I.; Ruhwald M.; Lundgren B.; Westh H.; Mathiesen L.R.; Ravn P.; Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-&#x3B3; test. Respir Res 2006,7(1),56 http:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/1465-9921-7-56","journal-title":"Respir Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/BOR.0b013e3283474d62","volume":"23","author":"Smith R.","year":"2011","unstructured":"Smith R.; Cattamanchi A.; Steingart K.R.; Denkinger C.; Dheda K.; Winthrop K.L.; Pai M.; Interferon-&#x3B3; release assays for diagnosis of latent tuberculosis infection: Evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011,23(4),377-384","journal-title":"Curr Opin Rheumatol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","volume":"16","author":"Goletti D.","year":"2018","unstructured":"Goletti D.; Petrone L.; Ippolito G.; Niccoli L.; Nannini C.; Cantini F.; Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther 2018,16(6),501-512","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/1756-185X.13129","volume":"20","author":"Handa R.","year":"2017","unstructured":"Handa R.; Upadhyaya S.; Kapoor S.; Jois R.; Pandey B.D.; Bhatnagar A.K.; Khanna A.; Goyal V.; Kumar K.; Tuberculosis and biologics in rheumatology: A special situation. Int J Rheum Dis 2017,20(10),1313-1325","journal-title":"Int J Rheum Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"Singh J.A.","year":"2012","unstructured":"Singh J.A.; Furst D.E.; Bharat A.; Curtis J.R.; Kavanaugh A.F.; Kremer J.M.; Moreland L.W.; O\u2019Dell J.; Winthrop K.L.; Beukelman T.; Bridges S.L.; Chatham W.W.; Paulus H.E.; Suarez-Almazor M.; Bombardier C.; Dougados M.; Khanna D.; King C.M.; Leong A.L.; Matteson E.L.; Schousboe J.T.; Moynihan E.; Kolba K.S.; Jain A.; Volkmann E.R.; Agrawal H.; Bae S.; Mudano A.S.; Patkar N.M.; Saag K.G.; 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012,64(5),625-639","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886316666211109092354","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197801\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886316666211109092354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T09:57:05Z","timestamp":1667469425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197801\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886316666211109092354","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}